MEI Pharma, a clinical-stage biotech firm, just made an unexpected pivot, allocating nine figures to Litecoin as a treasury asset. With GSR advising and Charlie Lee on board, the...
MEI Pharma, a clinical-stage biotech firm, just made an unexpected pivot, allocating nine figures to Litecoin as a treasury asset. With GSR advising and Charlie Lee on board, the...